Lunch Symposium

Abstract

The overall objectives of this session are to understand the patient burden of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) and to reflect on the role of tailored treatment strategies in the management of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The presentation will initially, for each of the 3 diseases, describe key disease characteristics and the clinical responses to different types of therapy, with emphasis on biological and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs). Subsequently, the focus will be the gap between patients’ and physicians’ perspectives on the most important aspects of the diseases, and on the main goals of treatment. Thereafter, current international recommendations for RA, PsA and axSpA and the treat-to-target concept will be introduced and discussed, followed by a discussion, disease by disease, of whether prevention of radiographic progression should be an important the goal of treatment. Finally, it will be discussed how the strategy for treating patients RA, PsA, and axSpA should be in the future, including the role of therapeutic strategies tailored for the individual patients.